Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
…, B Massuti, E Felip, R Palmero, R Garcia-Gomez… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
Encephalitis induced by immune checkpoint inhibitors: a systematic review
…, M Simó, N Vilariño, M Alemany, R Palmero… - JAMA …, 2021 - jamanetwork.com
… Dr Palmero reported receiving personal fees from Bristol Myers Squibb, Merck Sharp &
Dohme, Lilly, Roche, Boehringer Ingelheim, and AstraZeneca outside the submitted work. Dr …
Dohme, Lilly, Roche, Boehringer Ingelheim, and AstraZeneca outside the submitted work. Dr …
[HTML][HTML] Screening for epidermal growth factor receptor mutations in lung cancer
…, R Palmero, JM Sánchez, R Bastus… - … England Journal of …, 2009 - Mass Medical Soc
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
[HTML][HTML] Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer
…, C Aguado de la Rosa, R Palmero… - … England Journal of …, 2023 - Mass Medical Soc
Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …
receive a diagnosis of stage III disease. There is no current consensus regarding the most …
Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy
…, P Juarez-López, J LLuch, JA Narváez, R Palmero… - Autoimmunity …, 2018 - Elsevier
Objective To evaluate the prevalence and type of rheumatic immune-related adverse events
(IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors. Methods …
(IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors. Methods …
The HIV care continuum in Latin America: challenges and opportunities
…, J Sierra-Madero, P Cahn, RNG Palmero… - The Lancet Infectious …, 2015 - thelancet.com
Combination antiretroviral therapy (ART), also known as highly active antiretroviral therapy,
provides clinical and immunological benefits for people living with HIV and is an effective …
provides clinical and immunological benefits for people living with HIV and is an effective …
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm …
…, O Gautschi, S Peters, B Massutí, R Palmero… - The Lancet …, 2017 - thelancet.com
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
…, M Varela, JC Ruffinelli, R Palmero… - The Lancet …, 2018 - thelancet.com
Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing …
…, G Liu, F Cappuzzo, JR Contreras, M Reck, R Palmero… - The Lancet, 2023 - thelancet.com
Background Despite immunotherapy advancements for patients with advanced or metastatic
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …
Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non–small-cell lung cancer
R Palmero, A Taus, S Viteri, M Majem… - JCO Precision …, 2021 - ascopubs.org
Purpose Treatment guidelines for advanced non–small-cell lung cancer (aNSCLC)
recommend broad molecular profiling for targeted therapy selection. This study prospectively …
recommend broad molecular profiling for targeted therapy selection. This study prospectively …